MSD

@MSDInvents

We aspire to be the premier research-intensive biopharmaceutical company.

Global

MSD
@MSDInvents
Sep 30
Today at #EADVCongress, we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more: go.msd.com/~nel
00:00
MSD
@MSDInvents
Aug 4
Join us today at 9 a.m. ET to learn more about our Q2 2026 #earnings: go.msd.com/~6q2
00:00
MSD
@MSDInvents
Aug 4
Our Q2 2026 #earnings results are live: go.msd.com/~e4u Swipe below for perspective from Chairman and CEO Rob Davis.
MSD
@MSDInvents
Jul 24
Today we announced our initial post-approval access plans for our investigational HIV prevention option. We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can be accessed by those who need it in low- and
00:00
MSD
@MSDInvents
May 7
Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: go.msd.com/~q3y
00:00
1